Vera Health
AI-powered clinical search platform providing evidence-based answers to healthcare professionals.
Website: https://www.verahealth.ai/home
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Vera Health |
| Tagline | AI-powered clinical search platform providing evidence-based answers to healthcare professionals. [verahealth.ai, retrieved 2026] |
| Headquarters | San Francisco, United States [Morningstar / PR Newswire, October 2026] |
| Founded | 2024 [Crunchbase, retrieved 2026] |
| Stage | Series A [Tech.eu, October 2026] |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2), Taieb Bennani and Maxime Allouch [Crunchbase, retrieved 2026] [scalelist.com, retrieved 2026] |
| Funding Label | $10M+ |
| Total Disclosed Funding | ~$32,000,000 [Tech.eu, October 2026] [Crunchbase, retrieved 2026] |
Links
Public sources
- Website: https://www.verahealth.ai/home
Executive Summary
PUBLIC Vera Health is building an AI-powered clinical search platform for healthcare professionals, and it deserves investor attention now because the company has paired a large reported clinician footprint with a fresh $28.5 million Series A led by Threshold Ventures [Tech.eu, October 2026] [Fierce Healthcare, October 2026]. Founded in 2024 by Taieb Bennani and Maxime Allouch, the company traces its origin to a physician-family use case, with coverage describing the product as initially built for the founders’ physician fathers before expanding into a broader clinical search workflow [Tech.eu, October 2026] [The Journal du Net, October 2026].
The product positioning is relatively clear in public materials: Vera says it searches medical literature, ranks evidence, cites sources, and presents answers in a way that signals evidence strength, which is a narrower and more clinically opinionated proposition than a general-purpose LLM interface [verahealth.ai, retrieved 2026] [La Tribune, October 2026]. That distinction matters if the product can keep trust high in daily clinical use, and the reported partnership with the American College of Emergency Physicians adds some early signal that the company is trying to anchor distribution in medical societies rather than in consumer-style usage alone [finance.yahoo.com, March 2026] [verahealth.ai/blog, March 2026].
On team quality, the public record is stronger on academic pedigree than on operating history: Bennani is identified in coverage as a Yale and MIT graduate, while Allouch is described as an MIT graduate who also studied at HEC Paris [The Journal du Net, October 2026] [Crunchbase, retrieved 2026]. Public sources also describe the broader buildout as involving AI researchers from MIT alongside clinicians from institutions including Mayo Clinic and Yale, although those claims remain materially company-linked and should be read with that caveat [verahealth.ai/blog, 2026].
Capital formation has moved quickly. Vera announced a $28.5 million Series A in October 2026 with participation from Optum Ventures, Mantis VC, SV Angel, Y Combinator, and Gradient, bringing disclosed funding to roughly $32 million, according to multiple reports [Tech.eu, October 2026] [Crunchbase, retrieved 2026] [Fierce Healthcare, October 2026]. The business model is still the least defined part of the story in public reporting, since the platform is described as free to clinicians, which leaves monetization, buyer conversion, and enterprise packaging as open questions rather than settled facts [Tech.eu, October 2026] [verahealth.ai, retrieved 2026].
Over the next 12 to 18 months, the main items to watch are whether Vera can convert reported clinician usage into durable institutional relationships, whether country-specific guideline adaptation scales outside its early European strongholds, and whether a 12-person team can maintain product quality as distribution broadens [JDN English, October 2026] [Cinco Días, October 2026] [hitconsultant.net, October 2026]. The upside case is evident in the reported adoption curve, but the underwriting question is still commercial structure, not awareness.
Lightly corroborated -- Funding, founders, and broad positioning are corroborated by multiple public sources, but several material product and traction details remain company-reported or only partially independently verified.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | $10M+ (total disclosed ~$32,000,000) |
How the Company Got Here
PUBLIC
Vera Health is a San Francisco-based healthtech company founded in 2024 by Taieb Bennani and Maxime Allouch, according to the company’s Crunchbase profile and Y Combinator listing [Crunchbase] [Y Combinator]. The company describes its product in plain terms as AI-powered clinical decision support for healthcare providers, with a focus on evidence-based answers for clinicians rather than general consumer search [Y Combinator] [verahealth.ai, retrieved 2026].
The public record is still thin on formal corporate detail, which is typical for a company at this age, but the basic chronology is consistent across first-party sources. Y Combinator lists Vera Health among its companies, while the company website presents Vera as an evidence-based clinical answers platform and Crunchbase identifies San Francisco as headquarters and Bennani as co-founder [Y Combinator] [verahealth.ai, retrieved 2026] [Crunchbase]. Those sources support a simple milestone sequence: founded in 2024, launched through Y Combinator, and publicly positioned by 2026 around clinical AI search and decision support [Y Combinator] [verahealth.ai, retrieved 2026].
Lightly corroborated -- Confirmed primarily by Crunchbase, Y Combinator, and the company website; no state filing or legal entity document was available in the provided public source set.
Product and Technology
MIXED
Vera is presenting itself as a clinical search tool rather than a general-purpose medical chatbot, and the distinction matters because the public evidence points to retrieval, ranking, and citation as the core user experience. Company materials say the platform gives clinicians answers in seconds, evaluates the strength of sources, and surfaces evidence-backed responses for healthcare professionals [Vera Health, retrieved 2026]. Press coverage around the Series A describes the product as searching medical literature, identifying and ranking evidence, citing sources, and signaling claim strength, with one report saying it searches more than 60 million publications [La Tribune, October 2026] [Tech.eu, October 2026] [Maddyness, October 2026]. Those capability claims are directionally consistent across sources, but much of the underlying detail still traces back to company descriptions rather than an independent product review or verified public demo [Vera Health, retrieved 2026] [Morningstar / PR Newswire, October 2026].
The more interesting technical point is that Vera appears to be building workflow trust through evidence presentation, not just answer generation. Public sources describe study ranking by relevance, color-coded communication of evidence strength, and adaptation to specialty, practice setting, and country-specific guidelines [La Tribune, October 2026] [Y Combinator, retrieved 2026]. The platform also says it is multilingual across English, French, Spanish, Italian, German, and Japanese, among other languages, which fits with the company's reported traction in European markets [Vera Health Blog, 2026] [Cinco Días, October 2026]. A formally announced partnership with the American College of Emergency Physicians suggests one concrete path for domain validation: integrating ACEP clinical policies into the product for emergency medicine use cases [finance.yahoo.com, March 2026] [verahealth.ai/blog, March 2026] [Gradient, retrieved 2026].
The open technical question is less about whether Vera can generate answers and more about whether it can maintain clinical reliability across specialties, jurisdictions, and fast-moving literature. Publicly, the company says the service is free to clinicians and has grown largely through recommendations, which implies the product has found some usability fit before a fully visible monetization model [Tech.eu, October 2026] [Maddyness, October 2026]. What is still missing from the public record is independent evidence on accuracy benchmarking, error rates, model architecture, EHR integration depth, or enterprise deployment controls, so the product read today rests on a credible wedge, evidence-grounded search for clinicians, with limited third-party technical validation [Vera Health, retrieved 2026] [Fierce Healthcare, October 2026].
Lightly corroborated -- Product positioning and ACEP partnership are corroborated by company materials and multiple press reports, but several feature-level claims remain company-described rather than independently validated.
Where the Demand Sits
PUBLIC
Clinical search is gaining attention because clinicians face a simple operational problem: the volume of medical literature is rising faster than any individual can review, while AI interfaces are making retrieval feel immediate enough to fit into care workflows [Fierce Healthcare, October 2026] [La Tribune, October 2026]. For Vera, the commercial opening sits at the intersection of clinical decision support, medical knowledge platforms, and healthcare-specific AI assistants, but the public record here is thinner on formal market sizing than on usage signals [Tech.eu, October 2026] [Y Combinator].
The cleanest way to describe the addressable market is by analogy rather than by a claimed TAM. Public sources support that Vera is selling into clinician knowledge retrieval and decision support, not broad hospital IT, and that its early adoption is concentrated among physicians and other healthcare professionals rather than health system administrators [Fierce Healthcare, October 2026] [Cinco Días, October 2026]. No named third-party market report was provided in the source set with a defensible TAM, SAM, or SOM for AI clinical search specifically, so sizing should be treated as an open diligence item rather than inferred from general healthcare AI headlines.
A few public data points still help frame demand. Vera says it is used by more than 800,000 clinicians across 190 countries as of October 27, 2026, and multiple named publishers repeated that figure in funding coverage [Tech.eu, October 2026] [Fierce Healthcare, October 2026] [JDN English, October 2026]. Regional adoption claims are more specific in Europe, where coverage reported that roughly one in four physicians in Spain and Italy use the product, one in seven physicians in France use it, and France alone accounts for about 50,000 users [Cinco Días, October 2026] [The Journal du Net, October 2026]. Those are company-reported figures rather than audited deployment data, but they do indicate that demand is not limited to a narrow pilot environment.
| Public market signal | Reported figure | Relevance to Vera |
|---|---|---|
| Clinicians using Vera globally | 800,000+ | Suggests meaningful cross-border demand for clinical search workflows [Tech.eu, October 2026] [Fierce Healthcare, October 2026] |
| Countries reached | 190 | Implies a market that is global by default, with localization as a product requirement [JDN English, October 2026] [Tech.eu, October 2026] |
| Physicians in Spain and Italy using Vera | ~1 in 4 | Indicates unusually strong penetration claims in selected European markets [Cinco Días, October 2026] |
| Physicians in France using Vera | ~1 in 7 | Points to traction in another major European physician market [The Journal du Net, October 2026] |
| Users in France | ~50,000 | Gives one country-level anchor for adoption density [The Journal du Net, October 2026] |
The practical takeaway is that Vera appears to be addressing a large global workflow category even though the public evidence does not yet support a precise market size. The better-read signal at this stage is adoption intensity among clinicians, especially in Europe, rather than any top-down TAM narrative [Cinco Días, October 2026] [JDN English, October 2026].
Demand drivers in the source set are fairly consistent. The product is described as returning evidence-based answers quickly, citing literature and surfacing the strength of evidence, which maps to a familiar clinical need: compressing search time without asking clinicians to trust an uncited answer [La Tribune, October 2026] [verahealth.ai, retrieved 2026]. Vera also says the product adapts to specialty, practice setting, and country-specific guidelines, a feature set that matters because clinical practice is local in its standards even when the literature base is global [Y Combinator] [Cinco Días, October 2026]. If those capabilities hold in practice, the tailwind is straightforward: AI adoption in medicine is more likely to expand where the interface saves time and the output remains inspectable.
Adjacent and substitute markets matter because Vera is not competing only with direct AI-native peers. The closest adjacent category is legacy clinical reference and decision-support software, where clinicians already pay, or their institutions pay, for trusted knowledge bases and evidence summaries [Fierce Healthcare, October 2026]. The most obvious substitute market is general-purpose AI assistants used informally by clinicians, alongside conventional literature databases and search tools; that is likely why Vera is positioned in press coverage as a clinical search engine rather than a general chatbot [Tech.eu, October 2026] [La Tribune, October 2026]. In market terms, that means Vera may win not only by creating new budget, but by displacing time spent across UpToDate-style reference tools, database search, and general AI querying.
Regulatory and macro forces cut both ways. Healthcare remains a sector where evidence quality, source attribution, and alignment with local guidance matter more than they do in consumer AI, which gives products like Vera a clearer reason to exist if they can document provenance well [verahealth.ai, retrieved 2026] [La Tribune, October 2026]. At the same time, the product's expansion logic, including country-specific adaptation and partnerships with medical societies, publishers, and health systems, implies that scale is not only a software problem but also a content, compliance, and institutional-trust problem [mobihealthnews.com, October 2026] [finance.yahoo.com, March 2026]. That usually lengthens the path from clinician-level adoption to deeper enterprise penetration, even when user growth looks strong.
Lightly corroborated -- Market direction is supported by multiple named publishers, but formal TAM/SAM/SOM data is absent and several adoption figures are company-reported through media coverage.
Competitive Landscape
MIXED Vera Health sits in a crowded but still unsettled part of clinical software, positioned between legacy evidence tools that clinicians already trust and newer AI interfaces that promise faster answers with less workflow friction [Tech.eu, October 2026] [verahealth.ai, retrieved 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Vera Health | AI-powered clinical search platform for healthcare professionals | Series A, $28.5M announced in October 2026; total disclosed funding reported at $32M | Evidence-based answer generation with cited sources, evidence ranking, multilingual support, and adaptation to specialty, practice setting, and country-specific guidance, according to the company and coverage | [Tech.eu, October 2026] [Fierce Healthcare, October 2026] [verahealth.ai, retrieved 2026] |
| OpenEvidence | AI clinical information and search product for physicians | Not established in the provided sources | Named peer in clinical AI search for clinicians | [Structured Facts] |
| Glass Health | Clinical AI assistant / decision-support product | Not established in the provided sources | Named peer in AI-assisted clinical reasoning | [Structured Facts] |
| ClinicalKey AI | AI layer on top of medical knowledge and reference workflow | Not established in the provided sources | Adjacent reference-search competitor tied to established clinical content workflows | [Structured Facts] |
| UpToDate | Incumbent clinical reference and decision-support tool | Not established in the provided sources | Entrenched clinician trust and long-standing use in evidence lookup workflows | [Structured Facts] |
| ChatGPT for Clinicians | General-purpose AI assistant used in clinical contexts | Not a company-specific funding stage in the provided sources | Broad usability and low-friction interface as an adjacent substitute rather than a dedicated evidence product | [Structured Facts] |
The field breaks into three practical segments. eu, October 2026]. ai, retrieved 2026].
Vera's edge today appears to be distribution and product framing rather than a clearly demonstrated moat in proprietary content. Public coverage repeatedly cites more than 800,000 clinicians across 190 countries as of October 2026, and also points to unusually strong penetration in Spain, Italy, and France, which suggests early product-market fit among physicians rather than only pilot usage [Fierce Healthcare, October 2026] [Cinco Días, October 2026] [JDN English, October 2026]. That matters because clinician recommendation loops can compound if the product is free and fast enough for point-of-care use, but the durability is less certain: the underlying wedge, evidence-grounded search with citations and ranking, is intelligible to competitors and could be matched by better-capitalized platforms if they can pair model quality with trusted content relationships [verahealth.ai, retrieved 2026] [La Tribune, October 2026].
The exposure is just as clear. Vera also does not appear, on the public record provided here, to control the hospital or payer channel through named enterprise deployments, and the available sources do not verify a customer base of health systems that would create deeper switching costs [Tech.eu, October 2026] [Fierce Healthcare, October 2026]. Its ACEP partnership is relevant because it points to one route around that weakness, direct integration of society-backed clinical policies, but that still looks like an early template rather than broad channel ownership [finance.yahoo.com, March 2026] [verahealth.ai/blog, March 2026] [gradient.com].
The most plausible 18-month scenario is a sorting of the market by trust source rather than by raw model performance. Vera is a winner if medical societies and publishers increasingly prefer purpose-built clinical interfaces that cite evidence, localize guidance, and can be distributed clinician by clinician across borders, because the company already shows international adoption and has publicly stated plans to deepen society and health-system partnerships [Cinco Días, October 2026] [mobihealthnews.com, October 2026]. ai, retrieved 2026].
Opportunity
Upside case
Public sources If Vera Health can turn early clinician adoption into a trusted clinical workflow, the prize is not another medical AI app but a default evidence layer for point-of-care decision support across geographies and specialties [Fierce Healthcare, October 2026] [Cinco Días, October 2026].
The headline opportunity is straightforward. Vera is trying to sit one step upstream of the clinical answer, at the search-and-evidence-ranking layer, where trust is won by citation quality, speed, and local relevance rather than by raw model fluency alone [verahealth.ai, retrieved 2026] [La Tribune, October 2026]. That outcome looks reachable, not merely aspirational, because the public record already shows unusual distribution for a company founded in 2024: Vera says it is used by more than 800,000 clinicians in 190 countries, and multiple outlets independently repeated the same adoption figure around the October 2026 Series A announcement [Tech.eu, October 2026] [Fierce Healthcare, October 2026] [JDN English, October 2026]. The signal to watch is that this usage appears to have been built while the platform remained free to clinicians and while the company was still operating with a reported 12-person team, which suggests product resonance before any large-scale commercial buildout [JDN English, October 2026] [hitconsultant.net, October 2026].
The paths to outsized scale are easier to see if they are separated into distinct operating bets.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Society-backed clinical standard | Vera becomes a preferred search and evidence interface for specialty societies and their members, starting with emergency medicine and extending into other disciplines | Additional partnerships modeled on the ACEP relationship, which already brings ACEP clinical policies directly into Vera [finance.yahoo.com, March 2026] [verahealth.ai/blog, March 2026] | ACEP represents more than 40,000 emergency physicians, and Vera has already shown one template for embedding society content into workflow rather than asking clinicians to leave the product for guidelines [gradient.com, retrieved 2026] [finance.yahoo.com, March 2026] |
| Pan-European clinician utility | Vera deepens its strong early adoption in Southern and Western Europe and becomes a cross-border clinical reference layer adapted to local guidelines and languages | New capital earmarked for European expansion and country-specific adaptation [mobihealthnews.com, October 2026] [La Tribune, October 2026] | Coverage reports that roughly one in four physicians in Spain and Italy use Vera, roughly one in seven in France, and that the product is multilingual across English, French, Spanish, Italian, German, Japanese, and others [Cinco Días, October 2026] [Vera Health Blog, 2026] |
| Enterprise clinical infrastructure | Vera moves from individual clinician pull to institutional deployment with health systems, publishers, and medical knowledge partners | Partnerships with medical societies, publishers, and health systems funded by the Series A [mobihealthnews.com, October 2026] | The product position, literature search, evidence ranking, source citation, and specialty or country adaptation, maps well to institutions that need a governed knowledge layer rather than a consumer chatbot [verahealth.ai, retrieved 2026] [La Tribune, October 2026] |
The compounding logic is credible if the product keeps winning on trust. A clinician tool that cites sources, ranks evidence, and signals evidence strength has a natural usage flywheel: higher daily utility drives word-of-mouth within specialties, broader usage creates pressure to support more countries and guidelines, and better local adaptation makes the product more defensible against generic AI interfaces [verahealth.ai, retrieved 2026] [La Tribune, October 2026]. Public evidence suggests the first turn of that flywheel may already be underway, because the company says growth has come primarily through professional recommendations and because adoption appears clustered in countries where local-language and country-specific guideline support matter [Cinco Días, October 2026] [Vera Health Blog, 2026]. If Vera can layer society content and institutional partnerships on top of that clinician pull, each new content or distribution agreement should make the next one easier to win.
The size of the win is still best framed as a scenario, not a forecast. Public sources here do not provide a clean market-sizing study or a tightly matched public comparable, so the most defensible benchmark is strategic importance rather than a precise valuation multiple. If Vera were to become a widely adopted, society-linked, multilingual clinical knowledge utility across Europe and beyond, it could plausibly support a venture-scale outcome measured in the billions of dollars of enterprise value (scenario, not a forecast), particularly because investors in the October 2026 round included healthcare and platform-oriented firms such as Threshold Ventures and Optum Ventures, which typically underwrite category leaders rather than narrow point tools [Tech.eu, October 2026] [Fierce Healthcare, October 2026]. The public evidence is not sufficient to pin that upside to revenue today, but it is sufficient to say the company is pursuing a category where trusted workflow ownership, once established, can become unusually durable.
Lightly corroborated -- Core funding and adoption claims are corroborated by multiple public outlets, but several product-capability and partnership details rely on company materials or single-source reporting.
Sources
Public sources
[verahealth.ai, retrieved 2026] Vera Health - Evidence-Based Clinical Answers | https://www.verahealth.ai/home
[Morningstar / PR Newswire, October 2026] Vera Health Quietly Became One of the World’s Most Used Clinical Tools. Now It Has Raised $32 Million to Give Every Clinician in the World the Best Medical Knowledge in Seconds | https://www.morningstar.com/news/pr-newswire/20261027ph82184/vera-health
[Crunchbase, retrieved 2026] Vera Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vera-health
[Tech.eu, October 2026] From two doctors to 800,000 clinicians: Vera Health raises $28.5M | https://tech.eu/2026/10/27/from-two-doctors-to-800000-clinicians-vera-health-raises-285m/
[scalelist.com, retrieved 2026] Vera Health | https://scalelist.com/
[Fierce Healthcare, October 2026] Vera Health secures $28.5M series A for AI-driven clinical search engine | https://www.fiercehealthcare.com/finance/vera-health-secures-285m-series-ai-driven-clinical-search-engine
[The Journal du Net, October 2026] Deux Français ont bâti Vera, le ‘ChatGPT des médecins’, et lèvent 28,5 millions de dollars | https://www.journaldunet.com/intelligence-artificielle/1557223-vera-health-boucle-sa-serie-a-et-porte-ses-fonds-leves-a-32-millions-de-dollars/
[finance.yahoo.com, March 2026] Vera Health Partners with the American College of Emergency Physicians to Bring Trusted Emergency Medicine Guidance into the Vera Platform | https://finance.yahoo.com/
[verahealth.ai/blog, March 2026] Vera Health Partners with the American College of Emergency Physicians to Bring Trusted Emergency Medicine Guidance into the Vera Platform | https://www.verahealth.ai/blog
[verahealth.ai/blog, 2026] Vera Health Blog | https://www.verahealth.ai/blog
[JDN English, October 2026] Vera Health Raises $28.5 Million for Its AI Assistant Used by 800,000 Clinicians | https://www.journaldunet.com/en/1557237-vera-health-raises-28-5-million-for-its-ai-assistant-used-by-800-000-clinicians/
[Cinco Días, October 2026] Vera Health levanta 25,5 millones para su IA clínica, que es usada por uno de cada cuatro médicos en España | https://cincodias.elpais.com/companias/2026-10-27/vera-health-levanta-255-millones-para-su-ia-clinica-que-es-usada-por-uno-de-cada-cuatro-medicos-en-espana.shtml
[hitconsultant.net, October 2026] Vera Health Raises $28.5M to Scale AI Clinical Search Engine Used by 800,000 Clinicians | https://hitconsultant.net/
[Y Combinator, retrieved 2026] Vera Health: AI-powered clinical decision support for healthcare providers | https://www.ycombinator.com/companies/vera-health
[Vera Health, retrieved 2026] Vera Health - Evidence-Based Clinical Answers | https://www.verahealth.ai/home
[La Tribune, October 2026] Vera Health, le moteur de recherche des médecins, veut s’étendre en Europe après une levée de fonds de 29 millions d’euros | https://www.latribune.fr/article/tech/57183465372417/vera-health-le-moteur-de-recherche-des-medecins-veut-s-etendre-en-europe-apres-une-levee-de-fonds-de-29-millions-deuros
[Maddyness, October 2026] Deux Français passés par Y Combinator lèvent 32 millions de dollars pour leur moteur de recherche médical dopé à l’IA | https://www.maddyness.com/?p=1443499
[Vera Health Blog, 2026] Vera Health Blog | https://www.verahealth.ai/blog
[Gradient, retrieved 2026] Vera Health | https://gradient.com/
[mobihealthnews.com, October 2026] Vera Health raises $28.5M Series A | https://www.mobihealthnews.com/
[gradient.com, retrieved 2026] Vera Health | https://gradient.com/
Articles about Vera Health
- One in Four Spanish Physicians Now Use Vera Health's AI Search — The YC-backed startup, founded in 2024, raised a $28.5M Series A from Threshold and Optum to expand its evidence-based platform across Europe.